INS and breast carcinoma: PFK1 has been considered as a potential regulator of skeletal muscle insulin sensitivity and altered insulin-stimulated glucose metabolism, and differential expression of phosphofructokinase-1 isoforms also correlates with the glycolytic efficiency of breast cancer cells [39–41].